Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D014549 | Urinary Incontinence NIH | 1.00 |
| D004775 | Enuresis NIH | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000805 | Enuresis HPO | 1.00 |
| HP:0000020 | Urinary incontinence HPO | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
The increase of the older adult population in the past years has generated an important impact on chronic conditions and geriatric syndromes like dementia, falls and urinary incontinence (UI). To better understand IU seems warranted because of its socioeconomic and health impact. Nursing home (NH) residents are the frailest segment of our population, with very low physical activity levels and highly sedentary. Several studies had shown that physical activity levels and time and patterns of sedentary behaviour (SB) are independent risk factors for many health issues. As far as the investigators know, there is no evidence supporting the relation between IU and SB, and no information about the incidence of IU in NH residents living in Catalonia (Spain). This project consists of two stages: stage 1 will conduct a cross-sectional study using mixed methodology (qualitative and quantitative), and a 2-year longitudinal study (stage 2). Stage 1 has the main objective of verifying the prevalence of IU and its associated factors in NH residents in Barcelona (Spain), as well as analyse the association between IU (and their types) with SB time and patterns. In addition, the proportion of geriatric residents who receive control measures for their IU, and whether they receive SB-related interventions from health professionals of the institution will be also explored. Finally, the investigators aim to understand the experience of NH residents and the health professionals who care for them about the characteristics, burden and barriers of having IU. Stage 2 has the main objective to verify the incidence of the functional and continence decline, falls, hospitalizations and mortality, as well as their predictive factors in older care/nursing home residents in Barcelona (Spain). Specific objetives are to assess the evolution of each activity of daily living and the causes of hospitalization and death in geriatrics residents for a period of 2 years and to verify the incidence of recurrent falls (one or more falls), and analyse the consequences of falls (fractures, hospitalizations, among others) among the residents. Potential risk and protective factors for mortality due to COVID-19 and its impact on functioning and hospitalizations will also be analyzed. Finally, the stage 2 of the project aims at creating a specific instrument for the evaluation of frailty in institutionalized older people, based on the main predictive factors of functional decline.
Description: The presence of IU assessed by the Minimum Data Set (MDS) version 3.0
Measure: Urinary Incontinence Time: January 2020 to July 2020 (cross-sectional)Description: Patterns of sedentary behaviour (SB) with monitors (PAL Technologies, Scotland).
Measure: Patterns of sedentary behaviour Time: January 2020 to July 2020 (cross-sectional)Description: Modified (Likert 5-point scale) Barthel Index, assessed every 6 months
Measure: Functional decline Time: January 2020 to January 2022 (longitudinal, follow-up)Description: Minimum Data Set (MDS) version 3.0, assessed every 6 months
Measure: Continence decline Time: January 2020 to January 2022 (longitudinal, follow-up)Description: Prospective register of falls (date, place and consequence/s)
Measure: Incidence of falls Time: January 2020 to January 2022 (longitudinal, follow-up)Description: Prospective register of hospitalizations (date and cause)
Measure: Hospitalizations Time: January 2020 to January 2022 (longitudinal, follow-up)Description: Prospective register of deaths (date and cause)
Measure: Mortality Time: January 2020 to January 2022 (longitudinal, follow-up)Description: Sociodemographic variables (sex, age, civil status, education level, type of institution (public versus private / concerted) and time of residence in the institution.)
Measure: Sociodemographic variables Time: January 2020 to July 2020Description: Number and proportion of participants with lower urinary tract symptoms with the International Prostate Symptoms Score and urinary infection for the last 30 days.
Measure: Lower urinary tract symptoms Time: January 2020 to July 2020Description: Faecal incontinence according to Minimum Data Set version 3.0 (MDS 3.0)
Measure: Faecal incontinence Time: January 2020 to July 2020Description: Diary
Measure: Intake of liquids and diuretic drinks Time: January 2020 to July 2020Description: Dynamometer (2 trials per hand)
Measure: Handgrip strength Time: January 2020 to July 2020Description: Short Physical Performance Battery (SPPB)
Measure: Physical performance Time: January 2020 to July 2020Description: Rivermead Mobility Index
Measure: Mobility Time: January 2020 to July 2020Description: Clinical Frailty Scale
Measure: Frailty Time: January 2020 to July 2020Description: Modified (Likert 5-point scale) Barthel Index
Measure: Basic activities of daily living Time: January 2020 to July 2020Description: What kind of physical activity programme, the frequency of the sessions weekly, the dose of exercise of each session, the duration of the whole session, who provides the session, where the session is performed and if the session is individually or in group).
Measure: Physical activity programs Time: January 2020 to July 2020Description: What kind of programs are being applied to control and treat urinary and faecal incontinence in nursing homes
Measure: Incontinence programs Time: January 2020 to July 2020Description: According to the Anatomical Therapeutic Chemical classification system and the Defined Daily Dose (ATC/DDD)
Measure: Medication intake Time: January 2020 to July 2020Description: Number and proportion of participants with chronic diseases, delirium and pressure ulcers
Measure: Health conditions Time: January 2020 to July 2020Description: European Quality of Life-5 Dimensions; final score for Spain ranges between 1 (full health) to -0.654 (worse outcome)
Measure: Quality of life Time: January 2020 to July 2020Description: smoking and alcohol
Measure: Toxic habits Time: January 2020 to July 2020Description: Pfeiffer Scale, with final score ranging from 0 (normal) to 10 (total cognitive impairment)
Measure: Cognitive status Time: January 2020 to July 2020Description: 15-item Yesavage Geriatric Depression Scale, with final score ranging from 0 (normal) to 15 (severe depression)
Measure: Depressive symptoms Time: January 2020 to July 2020Description: Hospital Anxiety and Depression Scale (HADS), with final score ranging from 0 (normal) to 21 (severe anxiety)
Measure: Anxiety Time: January 2020 to July 2020Description: Using the NH register
Measure: Number births Time: January 2020 to July 2020Description: Using the NH register
Measure: Type of births Time: January 2020 to July 2020Description: During the last year, according to the NH register
Measure: Number of falls Time: January 2020 to July 2020Description: Mini Nutritional Assessment Test, ranging from 0 (malnutrition) to 30 (normal)
Measure: Nutritional status Time: January 2020 to July 2020Description: Amount of Vitamin D, albumin and pre-albumin, PCR (Protein C-Reactive) extracted from the routine analysis of the residents.
Measure: Biochemical evaluation Time: January 2020 to July 2020Description: Percentage (%) of body fat, % of fat-free mass and % of body water assessed by a Tanita TBF-300 bioimpedance device
Measure: Body composition Time: January 2020 to July 2020Description: Lubben Social Network Scale ranging from 0 to 30, with a higher score indicating more social engagement.
Measure: Social network Time: January 2020 to July 2020Description: 6-item Gierveld Loneliness Scale ranging from 0 (not lonely) to 6
Measure: Loneliness Time: January 2020 to July 2020Description: Date and result of diagnosis test/s for COVID-19 (PCR or serological antibody test)
Measure: COVID-19 Time: June 2020 to January 2022 (longitudinal, follow-up)Description: In the previous 6 months, the resident had symptoms compatible with COVID-19 (cough, fever and/or breathing difficulties) without COVID-19 diagnosis test confirmation
Measure: Suspected case of COVID-19 Time: June 2020 to January 2022 (longitudinal, follow-up)Description: Level of resident's frailty assessed with the Clinical Frailty Scale
Measure: Frailty Time: June 2020 to January 2022 (longitudinal, follow-up)Description: Any change in the regular medication in the last 6 months (include the name of the med, dose and the duration of treatment)
Measure: Change in medication Time: June 2020 to January 2022 (longitudinal, follow-up)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports